Trial Profile

A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luspatercept (Primary) ; Deferasirox
Indications Anaemia; Beta-thalassaemia; Myelodysplastic syndromes; Myelofibrosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms LTFU study
Sponsors Celgene Corporation

Most Recent Events

14 Feb 2024 Planned End Date changed from 25 Mar 2030 to 12 May 2028.
14 Feb 2024 Planned primary completion date changed from 25 Mar 2030 to 12 May 2028.
12 Dec 2023 Results (n=138) assessing Efficacy and Safety of Luspatercept presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com